EVOLVE
Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events
Patient / Population Intervention / Exposition Comparaison Critère de jugement
In 3,883 haemodialysis patients with secondary hyperparathyroidism, cinacalcet did not significantly reduce death or cardiovascular events compared with placebo.
N
3 883
Schéma
Double-blind RCT
Critère
Composite of death or first non-fatal cardiovascular event
Pertinence
2
Résultat48.2% vs 49.2%; HR 0.93 (95% CI 0.85–1.02; p=0.11); age-adjusted HR 0.88.
Chertow GM, et al. N Engl J Med. 2012;367(26):2482-2494. 10.1056/NEJMoa1205624
Discussion et critique
No universal CV benefit; high dropout and crossover; cinacalcet is now used selectively in refractory disease.